<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2678314-A1" country="EP" doc-number="2678314" kind="A1" date="20140101" family-id="45809628" file-reference-id="315082" date-produced="20180826" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="146551181" ucid="EP-2678314-A1"><document-id><country>EP</country><doc-number>2678314</doc-number><kind>A1</kind><date>20140101</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-12707190-A" is-representative="NO"><document-id mxw-id="PAPP154825104" load-source="docdb" format="epo"><country>EP</country><doc-number>12707190</doc-number><kind>A</kind><date>20120216</date><lang>EN</lang></document-id><document-id mxw-id="PAPP175260687" load-source="docdb" format="original"><country>EP</country><doc-number>12707190.0</doc-number><date>20120216</date><lang>EN</lang></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC140449674" ucid="US-201113031375-A" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>201113031375</doc-number><kind>A</kind><date>20110221</date></document-id></priority-claim><priority-claim mxw-id="PPC140449395" ucid="US-2012025335-W" linkage-type="W" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>2012025335</doc-number><kind>W</kind><date>20120216</date></document-id></priority-claim></priority-claims><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL-2049520398" load-source="docdb">C12P  23/00        20060101ALI20150528BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-2049522578" load-source="docdb">C07C 403/12        20060101AFI20150528BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-2049526481" load-source="docdb">C12P   7/62        20060101ALI20150528BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-2049527735" load-source="docdb">A61Q  19/00        20060101ALI20150528BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-2049527827" load-source="docdb">A61K   8/67        20060101ALI20150528BHEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL-1820254761" load-source="docdb" scheme="CPC">C07C2601/16        20170501 LA20170503BHEP        </classification-cpc><classification-cpc mxw-id="PCL1988102219" load-source="docdb" scheme="CPC">C07C 403/12        20130101 FI20131101BHEP        </classification-cpc><classification-cpc mxw-id="PCL1988108043" load-source="docdb" scheme="CPC">C12P   7/62        20130101 LI20131101BHEP        </classification-cpc><classification-cpc mxw-id="PCL1988114291" load-source="docdb" scheme="CPC">A61Q  19/00        20130101 LI20130101BHEP        </classification-cpc><classification-cpc mxw-id="PCL1988133460" load-source="docdb" scheme="CPC">C12P  23/00        20130101 LI20131101BHEP        </classification-cpc><classification-cpc mxw-id="PCL1988135869" load-source="docdb" scheme="CPC">A61K   8/85        20130101 LI20130621BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT132186027" lang="DE" load-source="patent-office">HYDROXYALKANSÄURE UND HYDROXYALKANSÄURE-OLIGOMERESTER AUS RETINOL</invention-title><invention-title mxw-id="PT132186028" lang="EN" load-source="patent-office">HYDROXYALKANOIC ACID AND HYDROXYALKANOIC ACID OLIGOMER ESTERS OF RETINOL</invention-title><invention-title mxw-id="PT132186029" lang="FR" load-source="patent-office">ESTERS D'OLIGOMÈRE D'ACIDE HYDROXYALCANOÏQUE ET D'ACIDE HYDROXYALCANOÏQUE DE RÉTINOL</invention-title></technical-data><parties><applicants><applicant mxw-id="PPAR918165872" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>EASTMAN CHEM CO</last-name><address><country>US</country></address></addressbook></applicant><applicant mxw-id="PPAR918138013" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>EASTMAN CHEMICAL COMPANY</last-name></addressbook></applicant><applicant mxw-id="PPAR918991382" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Eastman Chemical Company</last-name><iid>101095751</iid><address><street>200 South Wilcox Drive</street><city>Kingsport, TN 37660</city><country>US</country></address></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR918145927" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>BOAZ NEIL WARREN</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR918171402" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>BOAZ, NEIL, WARREN</last-name></addressbook></inventor><inventor mxw-id="PPAR918991859" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>BOAZ, NEIL, WARREN</last-name><address><street>P.O. Box 6332</street><city>Kingsport, TN 37663</city><country>US</country></address></addressbook></inventor></inventors><agents><agent mxw-id="PPAR918985475" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Brown, Fraser Gregory James</last-name><suffix>et al</suffix><iid>100042458</iid><address><street>Cleveland 10 Fetter Lane</street><city>London EC4A 1BR</city><country>GB</country></address></addressbook></agent></agents></parties><international-convention-data><pct-or-regional-filing-data ucid="US-2012025335-W"><document-id><country>US</country><doc-number>2012025335</doc-number><kind>W</kind><date>20120216</date><lang>EN</lang></document-id></pct-or-regional-filing-data><pct-or-regional-publishing-data ucid="WO-2012154243-A1"><document-id><country>WO</country><doc-number>2012154243</doc-number><kind>A1</kind><date>20121115</date><lang>EN</lang></document-id></pct-or-regional-publishing-data><designated-states><ep-contracting-states><country mxw-id="DS548924638" load-source="docdb">AL</country><country mxw-id="DS548864769" load-source="docdb">AT</country><country mxw-id="DS548836643" load-source="docdb">BE</country><country mxw-id="DS548933692" load-source="docdb">BG</country><country mxw-id="DS548815482" load-source="docdb">CH</country><country mxw-id="DS548836644" load-source="docdb">CY</country><country mxw-id="DS548927986" load-source="docdb">CZ</country><country mxw-id="DS548924639" load-source="docdb">DE</country><country mxw-id="DS548836645" load-source="docdb">DK</country><country mxw-id="DS548836646" load-source="docdb">EE</country><country mxw-id="DS548912271" load-source="docdb">ES</country><country mxw-id="DS548933693" load-source="docdb">FI</country><country mxw-id="DS548933694" load-source="docdb">FR</country><country mxw-id="DS548924640" load-source="docdb">GB</country><country mxw-id="DS548836647" load-source="docdb">GR</country><country mxw-id="DS548924641" load-source="docdb">HR</country><country mxw-id="DS548927987" load-source="docdb">HU</country><country mxw-id="DS548815483" load-source="docdb">IE</country><country mxw-id="DS548836648" load-source="docdb">IS</country><country mxw-id="DS548933695" load-source="docdb">IT</country><country mxw-id="DS548836649" load-source="docdb">LI</country><country mxw-id="DS548933696" load-source="docdb">LT</country><country mxw-id="DS548864770" load-source="docdb">LU</country><country mxw-id="DS548933697" load-source="docdb">LV</country><country mxw-id="DS548933702" load-source="docdb">MC</country><country mxw-id="DS548864771" load-source="docdb">MK</country><country mxw-id="DS548864772" load-source="docdb">MT</country><country mxw-id="DS548864773" load-source="docdb">NL</country><country mxw-id="DS548815484" load-source="docdb">NO</country><country mxw-id="DS548864774" load-source="docdb">PL</country><country mxw-id="DS548912272" load-source="docdb">PT</country><country mxw-id="DS548925898" load-source="docdb">RO</country><country mxw-id="DS548912273" load-source="docdb">RS</country><country mxw-id="DS548864775" load-source="docdb">SE</country><country mxw-id="DS548924642" load-source="docdb">SI</country><country mxw-id="DS548815485" load-source="docdb">SK</country><country mxw-id="DS548815486" load-source="docdb">SM</country><country mxw-id="DS548836650" load-source="docdb">TR</country></ep-contracting-states></designated-states></international-convention-data><office-specific-data><eptags><ep-no-a-document-published>*</ep-no-a-document-published></eptags></office-specific-data></bibliographic-data><abstract mxw-id="PA101900412" ref-ucid="WO-2012154243-A1" lang="EN" load-source="patent-office"><p num="0000">Retinyl hydroxyesters and retinyl oligo-hydroxyesters were prepared using a chemoenzymatic process from retinol and short chain esters of hydroxycarboxylic acids or short chain esters of hydroxycarboxylic acids. The presence of the hydroxyl group on the acid can result in a mixture of esters from various oligomers of the hydroxycarboxylic acid. The retinyl ester products are readily enzymatically hydrolyzed in vitro, which indicates that application to the skin should result in release of the anti-aging ingredient retinol (without the inherent instability and irritation) along with the acid, which, if chosen appropriately, should also have desirable biological effects. This combination should be effective as an anti-aging skin care ingredient.</p></abstract><abstract mxw-id="PA102368320" ref-ucid="WO-2012154243-A1" lang="EN" source="national office" load-source="docdb"><p>Retinyl hydroxyesters and retinyl oligo-hydroxyesters were prepared using a chemoenzymatic process from retinol and short chain esters of hydroxycarboxylic acids or short chain esters of hydroxycarboxylic acids. The presence of the hydroxyl group on the acid can result in a mixture of esters from various oligomers of the hydroxycarboxylic acid. The retinyl ester products are readily enzymatically hydrolyzed in vitro, which indicates that application to the skin should result in release of the anti-aging ingredient retinol (without the inherent instability and irritation) along with the acid, which, if chosen appropriately, should also have desirable biological effects. This combination should be effective as an anti-aging skin care ingredient.</p></abstract><abstract mxw-id="PA101900413" ref-ucid="WO-2012154243-A1" lang="FR" load-source="patent-office"><p num="0000">La présente invention concerne des hydroxyesters de rétinyle et des oligo-hydroxyesters de rétinyle qui sont préparés en utilisant un procédé chimioenzymatique à partir de rétinol et d'esters à chaîne courte d'acides hydroxycarboxyliques ou d'esters à chaîne courte d'acides hydroxycarboxyliques. La présence du groupe hydroxyle sur l'acide peut conduire à un mélange d'esters à partir de différents oligomères de l'acide hydroxycarboxylique. Les produits d'ester de rétinyle sont aisément hydrolysés par voie enzymatique <i>in vitro</i>, ce qui indique que l'application sur la peau doit conduire à la libération du composant antivieillissement rétinol (sans l'instabilité et l'irritation inhérente) avec l'acide, qui, s'il est choisi de manière appropriée, doit également avoir des effets biologiques souhaitables. Cette combinaison doit être efficace en tant que composant de soin de la peau antivieillissement.</p></abstract><abstract mxw-id="PA102368321" ref-ucid="WO-2012154243-A1" lang="FR" source="national office" load-source="docdb"><p>La présente invention concerne des hydroxyesters de rétinyle et des oligo-hydroxyesters de rétinyle qui sont préparés en utilisant un procédé chimioenzymatique à partir de rétinol et d'esters à chaîne courte d'acides hydroxycarboxyliques ou d'esters à chaîne courte d'acides hydroxycarboxyliques. La présence du groupe hydroxyle sur l'acide peut conduire à un mélange d'esters à partir de différents oligomères de l'acide hydroxycarboxylique. Les produits d'ester de rétinyle sont aisément hydrolysés par voie enzymatique in vitro, ce qui indique que l'application sur la peau doit conduire à la libération du composant antivieillissement rétinol (sans l'instabilité et l'irritation inhérente) avec l'acide, qui, s'il est choisi de manière appropriée, doit également avoir des effets biologiques souhaitables. Cette combinaison doit être efficace en tant que composant de soin de la peau antivieillissement.</p></abstract><description mxw-id="PDES52505125" ref-ucid="WO-2012154243-A1" lang="EN" load-source="patent-office"><!-- EPO <DP n="2"/>--><p id="p0001" num="0001"> HYDROXYALKANOIC ACID AND HYDROXYALKANOIC ACID OLIGOMER</p><p id="p0002" num="0002">ESTERS OF RETINOL </p><p id="p0003" num="0003">FIELD OF THE INVENTION </p><p id="p0004" num="0004">The present invention relates to retinyl esters and to processes for producing them. BACKGROUND OF THE INVENTION </p><p id="p0005" num="0005">Retinol (Vitamin A) and its derivatives have a long history as active ingredients in cosmetic compositions to improve the overall appearance of the skin. Retinol itself is unstable and is irritating upon excessive use. Long- chain retinyl esters are therefore sometimes preferred because they are more stable and less irritating to the skin. These esters are expected to be readily hydrolyzed in the skin to afford retinol for metabolism and thus efficacy. </p><p id="p0006" num="0006">Depending on the fatty acid portion of the retinyl ester, the fatty acid hydrolysis product may provide additional benefits. Besides fatty acids, other structures, with various biological properties, are also desired in retinyl conjugates, in order to improve and/or broaden the biological benefits. </p><p id="p0007" num="0007"> Chemical preparation of retinyl esters involves either the reaction of retinol with a long chain acid, acid chloride, or an ester, or by the </p><p id="p0008" num="0008">transesterification of a short-chain retinyl ester with a long-chain fatty acid ester. These processes use either harsh reagents or high temperatures, which can cause degradation due to the instability of the retinol or the retinyl esters to these types of reaction conditions. In addition, these methods are generally incompatible with components having reactive functionalities such as alcohols, unless the alcohols are protected. The protection-deprotection adds cost, time, and waste to the synthesis of these types of molecules. 
<!-- EPO <DP n="3"/>-->
 There have been several reports of biocatalytic syntheses of retinyl esters from retinol (O'Connor et. al. Aust. J. Chem. 1992, 45, 641 ; Maugard, et. al. J. Mol. Catal. B: Enzymatic 2000, 8, 275; Maugard et. al., Biotechnol. Prog. 2000, 16, 358; Maugard et. al. Biotechnol. Prog. 2002, 18, 424.). These methods typically use long-chain acids that facilitate the ester formation and lack complicating reactive groups. An exception is retinyl lactate, which has been prepared by enzymatic esterification of retinol with methyl lactate </p><p id="p0009" num="0009">(Maugard, et. al. J. Mol. Catal. B: Enzymatic 2000, 8, 275; Maugard et. al., Biotechnol. Prog. 2000, 16, 358; Maugard et. al. Biotechnol. Prog. 2002, 18, 424.). This is an unusual case, as the steric hindrance around the hydroxyl group of the lactate renders it relatively unreactive toward enzymatic esterification. </p><p id="p0010" num="0010"> Retinyl esters tend to be more stable and more innocuous than retinol itself. The acid piece can be chosen for these purposes, or can be influenced by other biological considerations. For example, 3-hydroxybutyric acid and esters thereof, including oligomers, are well-known to be cellular energy sources, as noted by Stryer in Biochemistry, 4<sup>th</sup> edition (1995), p 613, where he states that "Acetoacetate and β-hydroxybutyrate are normal fuels of respiration and are quantitatively important as sources of energy." A coupling of β-hydroxybutyrate or its oligomers with retinol, should it hydrolyze to the constituent acid and alcohol in the cell, could have a double effect - retinol would promote differentiation while the hydroxybutyrate would provide energy. </p><p id="p0011" num="0011"> Thus retinyl esters of 3-hydroxybutyrate and 3-hydroxybutyrate oligomers as well as other hydroxyalkanoates would be novel materials that should be of advantage in cosmetic anti-aging compositions. 
<!-- EPO <DP n="4"/>-->
 SUMMARY OF THE INVENTION </p><p id="p0012" num="0012">In one aspect, the invention relates to retinyl esters represented by the general formula 1 : </p><p id="p0013" num="0013"><img id="imgf000004_0001" he="20" wi="96" file="imgf000004_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></p><p id="p0014" num="0014">1 </p><p id="p0015" num="0015">wherein R is selected from substituted and unsubstituted, branched- and straight-chain, saturated, unsaturated, and polyunsaturated divalent C1 -C22 alkyi, substituted and unsubstituted divalent C<sub>3</sub>-C<sub>8</sub> cycloalkyi, substituted and unsubstituted divalent C<sub>6</sub>-C<sub>2</sub>o carbocyclic aryl, and substituted and </p><p id="p0016" num="0016">unsubstituted divalent C<sub>4</sub>-C<sub>2</sub>o heterocyclic wherein the heteroatoms are selected from sulfur, nitrogen, and oxygen; R<sup>1</sup> is selected from hydrogen, substituted and unsubstituted, branched- and straight-chain, saturated, unsaturated, and polyunsaturated C1 -C22 alkyi, substituted and unsubstituted C<sub>3</sub>-C<sub>8</sub> cycloalkyi, substituted and unsubstituted C<sub>6</sub>-C<sub>2</sub>o carbocyclic aryl, and substituted and unsubstituted C<sub>4</sub>-C<sub>2</sub>o heterocyclic wherein the heteroatoms are selected from sulfur, nitrogen, and oxygen; and n is 0-10; and mixtures of the foregoing esters. </p><p id="p0017" num="0017"> In another aspect, R is selected from substituted and unsubstituted, branched- and straight-chain, saturated, unsaturated, and polyunsaturated divalent C-|-C-|<sub>8</sub> alkyi, or a saturated or monounsatu rated straight-chain C-i -C-io alkyi; and R<sup>1</sup> is selected from hydrogen, substituted and unsubstituted, branched- and straight-chain, saturated, unsaturated, and polyunsaturated Ci - C18 alkyi, and n is 0-10. </p><p id="p0018" num="0018"> In another aspect, R is a substituted or unsubstituted, branched- or straight-chain, saturated, unsaturated, or polyunsaturated divalent C-I-C-I<sub>O</sub> alkyi, or a saturated or monounsatu rated straight-chain C1 -C4 alkyi; and R<sup>1</sup> is 
<!-- EPO <DP n="5"/>-->
 hydrogen, a substituted or unsubstituted, branched- or straight-chain, saturated, unsaturated, or polyunsaturated C ds alkyl, or C-1 -C-12 alkyl, or Ci- C<sub>4</sub> alkyl; and n is 0-6, or mixtures thereof. </p><p id="p0019" num="0019"> In yet another aspect, R is methyl, ethyl, or propyl; R<sup>1</sup> is methyl, ethyl, or propyl; and n is from 0 to 6, or mixtures thereof. In a further aspect, R is methylene; R<sup>1</sup> is methyl, and n= 1 , 2, 3, and 4. That is, the retinyl esters may be a mixture of esters of varying lengths and including repeating units. </p><p id="p0020" num="0020"> In another aspect, the retinyl esters may be derived from retinol and one or more hydroxy-substituted carboxylic acids, for example one or more of 3- hydroxybutyric acid, 3-hydroxy-3-methylbutyric acid, 3-hydroxyoctanoic acid, malic acid, 3-phenyl-3-hydroxypropanoic acid, 10-hydroxydecanoic acid, 12- hydroxydodecanoic acid, 16-hydroxyhexadecanoic acid, or ricinoleic acid. </p><p id="p0021" num="0021"> In another aspect, the esters include oligomers comprised of more than one repeating unit from the one or more hydroxy-substituted carboxylic acids. </p><p id="p0022" num="0022"> In a further aspect, the invention relates to processes for producing the retinyl esters just described, the processes comprising reacting retinol, in the presence of an enzyme, with an acid or short chain ester of a </p><p id="p0023" num="0023">hydroxyalkanoate represented by formula 2 o R<sup>1</sup> </p><p id="p0024" num="0024"> R<sup>5</sup>0 X R OH </p><p id="p0025" num="0025">wherein R and R<sup>1</sup> are as already indicated, and R<sup>5</sup> is chosen from hydrogen or C1 -C5 straight or branched chain alkane or alkene. </p><p id="p0026" num="0026"> The processes may be carried out in a solvent chosen from diethyl ether, diisopropyl ether, tert-butyl methyl ether, tetrahydrofuran, benzene, toluene, xylene, hexane, heptane, cyclohexane, limonene, dichloromethane, 
<!-- EPO <DP n="6"/>-->
 dichloroethane, dibromoethane, tetrachloroethylene, chlorobenzene, acetonitrile, dimethyl formamide, or dimethyl sulfoxide, or mixtures thereof. </p><p id="p0027" num="0027"> In another aspect, the process may be carried out in one or more of toluene, limonene, a heptane, or acetonitrile. Alternatively, the process may be carried out in the absence of a solvent. Enzymes useful according to the process of the invention include one or more of a lipase, an esterase, or a protease, and especially a lipase. </p><p id="p0028" num="0028"> In one aspect, the acid or short chain ester of a hydroxyalkanoate represented by formula 2 may comprise one or more of ethyl 3- hydroxybutyrate or methyl 3-hydroxybutyrate. </p><p id="p0029" num="0029"> In yet another aspect, the invention relates to cosmetic compositions that include the retinyl esters of the invention. </p><p id="p0030" num="0030"> Further aspects of the invention are as disclosed and claimed herein. DETAILED DESCRIPTION </p><p id="p0031" num="0031">As used herein, the terms "alkyl" and "alkyl groups" are intended to apply broadly to hydrocarbyl groups without regard to whether the carbons are joined together with a single bond, a double bond, or even a triple bond, so long as the groups contain linked carbon atoms and hydrogen atoms, some of which hydrogen atoms may be substituted by other atoms or groups of atoms, as is well-known in the art of organic chemistry. </p><p id="p0032" num="0032"> Thus, in one aspect, the invention relates to retinyl esters represented by the general formula 1 :</p><p id="p0033" num="0033"><img id="imgf000006_0001" he="20" wi="96" file="imgf000006_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></p><p id="p0034" num="0034"> 1 
<!-- EPO <DP n="7"/>-->
 wherein R is selected from substituted and unsubstituted, branched- and straight-chain, saturated, unsaturated, and polyunsaturated divalent C1-C22 alkyl, substituted and unsubstituted divalent C<sub>3</sub>-C<sub>8</sub> cycloalkyi, substituted and unsubstituted divalent C<sub>6</sub>-C<sub>2</sub>o carbocyclic aryl, and substituted and </p><p id="p0035" num="0035">unsubstituted divalent C<sub>4</sub>-C<sub>2</sub>o heterocyclic wherein the heteroatoms are selected from sulfur, nitrogen, and oxygen, and R<sup>1</sup> is selected from hydrogen, substituted and unsubstituted, branched- and straight-chain, saturated, unsaturated, and polyunsaturated C1-C22 alkyl, substituted and unsubstituted C<sub>3</sub>-C<sub>8</sub> cycloalkyi, substituted and unsubstituted C<sub>6</sub>-C<sub>2</sub>o carbocyclic aryl, and substituted and unsubstituted C<sub>4</sub>-C<sub>2</sub>o heterocyclic wherein the heteroatoms are selected from sulfur, nitrogen, and oxygen, and n is 0-10 or mixtures thereof. </p><p id="p0036" num="0036"> The compounds of the invention may be racemic, enantiomerically enriched, diasteroemerically enriched, substantially diastereomerically pure, or substantially enantiomerically pure. </p><p id="p0037" num="0037"> In another aspect, the invention relates to species denoted by structures 1 wherein R is selected from substituted and unsubstituted, branched- and straight-chain saturated divalent Ci-C-i<sub>8</sub> alkyl, substituted and unsubstituted, branched- and straight-chain divalent C<sub>2</sub>-Ci<sub>8</sub> alkenyl, substituted and unsubstituted, branched- and straight-chain divalent C<sub>4</sub>-C-|<sub>8</sub> dienyl, substituted and unsubstituted divalent C<sub>3</sub>-C<sub>8</sub> cycloalkyi, substituted and unsubstituted divalent C<sub>6</sub>-Ci<sub>2</sub> carbocyclic aryl, substituted and unsubstituted divalent C<sub>4</sub>-d<sub>2</sub> heterocyclic, R<sup>1</sup> is selected from hydrogen, substituted and unsubstituted, branched- and straight-chain saturated C-i-C-i<sub>8</sub> alkyl, substituted and unsubstituted, branched- and straight-chain C<sub>2</sub>-Ci<sub>8</sub> alkenyl, substituted and unsubstituted, branched- and straight-chain C<sub>4</sub>-Ci<sub>8</sub> dienyl, substituted and unsubstituted C<sub>3</sub>-C<sub>8</sub> cycloalkyi, substituted and unsubstituted C<sub>6</sub>-C-|<sub>2</sub> carbocyclic aryl, substituted and unsubstituted C<sub>4</sub>-C-|<sub>2</sub> heterocyclic, n is 0-6, or mixtures thereof. 
<!-- EPO <DP n="8"/>-->
 The saturated, unsaturated, and polyunsaturated alkyl and cycloalkyl groups which may be represented by R may be straight- or branched-chain divalent hydrocarbon radicals containing up to about 22 carbon atoms and may be substituted, for example, with one to five groups selected from C-i -C<sub>6</sub>- alkoxy, carboxyl, amino, C1 -C-15 aminocarbonyl, C1 -C-15 amido, cyano, C<sub>2</sub>-C<sub>6</sub>- alkoxycarbonyl, C<sub>2</sub>-C<sub>6</sub>-alkanoyloxy, hydroxy, aryl, heteroaryl, thiol, thioether, C2-C10 dialkylamino, C3-C-15 trialkylammonium and halogen. The terms "C-| -C<sub>6</sub>- alkoxy", "C<sub>2</sub>-C<sub>6</sub>-alkoxycarbonyl", and "C<sub>2</sub>-C<sub>6</sub>-alkanoyloxy" are used to denote radicals corresponding to the structures -OR<sup>2</sup>, -CO<sub>2</sub>R<sup>2</sup>, and -OCOR<sup>2</sup>, respectively, wherein R<sup>2</sup> is CrC<sub>6</sub>-alkyl or substituted CrC<sub>6</sub>-alkyl. The terms "C-1 -C-15 aminocarbonyl" and "C1 -C-15 amido" are used to denote radicals corresponding to the structures -N HCOR<sup>3</sup>, -CON H R<sup>3</sup>, respectively, wherein R<sup>3</sup> is CrCi<sub>5</sub>-alkyl or substituted C Ci<sub>5</sub>-alkyl. The term "C<sub>3</sub>-C<sub>8</sub>-cycloalkyl" is used to denote a saturated, carbocyclic hydrocarbon radical having three to eight carbon atoms. The term "halogen" is used to include fluorine, chlorine, bromine, and iodine. </p><p id="p0038" num="0038"> The saturated, unsaturated, and polyunsaturated alkyl groups which may be represented by R<sup>1</sup> may be straight- or branched-chain hydrocarbon radicals containing up to about 22 carbon atoms and may be substituted, for example, with one to five groups selected from C-i -C<sub>6</sub>-alkoxy, carboxyl, amino, C-1 -C-15 aminocarbonyl, C1 -C15 amido, cyano, C<sub>2</sub>-C<sub>6</sub>-alkoxycarbonyl, C<sub>2</sub>-C<sub>6</sub>- alkanoyloxy, hydroxy, aryl, heteroaryl, thiol, thioether, C<sub>2</sub>-do dialkylamino, C<sub>3</sub>- C-15 trialkylammonium and halogen. The terms "C-i -C<sub>6</sub>-alkoxy", "C<sub>2</sub>-C<sub>6</sub>- alkoxycarbonyl", and "C<sub>2</sub>-C<sub>6</sub>-alkanoyloxy" are used to denote radicals corresponding to the structures -OR<sup>2</sup>, -CO<sub>2</sub>R<sup>2</sup>, and -OCOR<sup>2</sup>, respectively, wherein R<sup>2</sup> is CrC<sub>6</sub>-alkyl or substituted CrC<sub>6</sub>-alkyl. The terms "C1 -C15 aminocarbonyl" and "C1 -C-15 amido" are used to denote radicals </p><p id="p0039" num="0039">corresponding to the structures -N HCOR<sup>3</sup>, -CON H R<sup>3</sup>, respectively, wherein R<sup>3</sup> is CrCi<sub>5</sub>-alkyl or substituted C Ci<sub>5</sub>-alkyl. The term "C<sub>3</sub>-C<sub>8</sub>-cycloalkyl" is used to denote a saturated, carbocyclic hydrocarbon radical having three to 
<!-- EPO <DP n="9"/>-->
 eight carbon atoms. The term "halogen" is used to include fluorine, chlorine, bromine, and iodine. </p><p id="p0040" num="0040"> The branching and/or substitution of R and R<sup>1</sup> may connect to form a ring. The aryl groups which R may represent may include divalent phenyl, naphthyl, or anthracenyl and divalent phenyl, naphthyl, or anthracenyl substituted with one to five substituents selected from CrC<sub>6</sub>-alkyl, substituted Ci-C<sub>6</sub>-alkyl, C<sub>6</sub>-C-|<sub>0</sub> aryl, substituted C<sub>6</sub>-C-|<sub>0</sub> aryl, C-i-C<sub>6</sub>-alkoxy, halogen, carboxy, cyano, C-i-C<sub>6</sub>-alkanoyloxy, C-i-C<sub>6</sub>-alkylthio, C-i-C<sub>6</sub>-alkylsulfonyl, trifluoromethyl, hydroxy, C<sub>2</sub>-C<sub>6</sub>-alkoxycarbonyl, C<sub>2</sub>-C<sub>6</sub>-alkanoylamino and - OR<sup>4</sup>, -S-R<sup>4</sup>, -SO2-R<sup>4</sup>, -NHSO2R<sup>4</sup> and -NHCO<sub>2</sub>R<sup>4</sup>, wherein R<sup>4</sup> is phenyl, naphthyl, or phenyl or naphthyl substituted with one to three groups selected from Ci-C<sub>6</sub>-alkyl, C<sub>6</sub>-C-|<sub>0</sub> aryl, C-i-C<sub>6</sub>-alkoxy and halogen. The term "halogen" is used to include fluorine, chlorine, bromine, and iodine. </p><p id="p0041" num="0041"> The aryl groups which R<sup>1</sup> may represent (or any aryl substituents) may include phenyl, naphthyl, or anthracenyl and phenyl, naphthyl, or anthracenyl substituted with one to five substituents selected from CrC<sub>6</sub>-alkyl, substituted d-Ce-alkyl, C<sub>6</sub>-Ci<sub>0</sub> aryl, substituted C<sub>6</sub>-Ci<sub>0</sub> aryl, CrC<sub>6</sub>-alkoxy, halogen, carboxy, cyano, CrC<sub>6</sub>-alkanoyloxy, CrC<sub>6</sub>-alkylthio, CrC<sub>6</sub>-alkylsulfonyl, trifluoromethyl, hydroxy, C<sub>2</sub>-C<sub>6</sub>-alkoxycarbonyl, C<sub>2</sub>-C<sub>6</sub>-alkanoylamino and - OR<sup>4</sup>, -S-R<sup>4</sup>, -SO<sub>2</sub>-R<sup>4</sup>, -NHSO<sub>2</sub>R<sup>4</sup> and -NHCO<sub>2</sub>R<sup>4</sup>, wherein R<sup>4</sup> is phenyl, naphthyl, or phenyl or naphthyl substituted with one to three groups selected from d-Ce-alkyl, C<sub>6</sub>-Ci<sub>0</sub> aryl, CrC<sub>6</sub>-alkoxy and halogen. The term "halogen" is used to include fluorine, chlorine, bromine, and iodine. </p><p id="p0042" num="0042"> The divalent heterocyclic groups which R may represent include 5- or 6- membered ring containing one to three heteroatoms selected from oxygen, sulfur and nitrogen. Examples of such heterocyclic groups are pyranyl, oxopyranyl, dihydropyranyl, oxodihydropyranyl, tetrahydropyranyl, thienyl, furyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, thiadiazolyl, oxadiazolyl, tetrazolyl, pyridyl, pyrimidyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, indolyl and the like. The heterocyclic radicals 
<!-- EPO <DP n="10"/>-->
 may be substituted, for example, with up to three groups such as Ci-C<sub>6</sub>-alkyl, d-Ce-alkoxy, substituted CrC<sub>6</sub>-alkyl, halogen, CrC<sub>6</sub>-alkylthio, aryl, arylthio, aryloxy, C<sub>2</sub>-C<sub>6</sub>-alkoxycarbonyl and C<sub>2</sub>-C<sub>6</sub>-alkanoylamino. The heterocyclic radicals also may be substituted with a fused ring system, e.g., a benzo or naphtho residue, which may be unsubstituted or substituted, for example, with up to three of the groups set forth in the preceding sentence. The term </p><p id="p0043" num="0043">"halogen" is used to include fluorine, chlorine, bromine, and iodine. </p><p id="p0044" num="0044"> The heterocyclic groups which R<sup>1</sup> may represent (or any heteroaryl substituents) include 5- or 6- membered ring containing one to three heteroatoms selected from oxygen, sulfur and nitrogen. Examples of such heterocyclic groups are pyranyl, oxopyranyl, dihydropyranyl, </p><p id="p0045" num="0045">oxodihydropyranyl, tetrahydropyranyl, thienyl, furyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, thiadiazolyl, oxadiazolyl, tetrazolyl, pyridyl, pyrimidyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, indolyl and the like. The heterocyclic radicals may be substituted, for example, with up to three groups such as Ci-C<sub>6</sub>-alkyl, C-|-C<sub>6</sub>- alkoxy, substituted Ci-C<sub>6</sub>-alkyl, halogen, Ci-C<sub>6</sub>-alkylthio, aryl, arylthio, aryloxy, C<sub>2</sub>-C<sub>6</sub>-alkoxycarbonyl and C<sub>2</sub>-C<sub>6</sub>-alkanoylamino. The heterocyclic radicals also may be substituted with a fused ring system, e.g., a benzo or naphtho residue, which may be unsubstituted or substituted, for example, with up to three of the groups set forth in the preceding sentence. The term "halogen" is used to include fluorine, chlorine, bromine, and iodine. </p><p id="p0046" num="0046"> Examples of the compounds of the invention include those represented by formula 1 wherein R is methylene, R<sup>1</sup> is methyl and n is from 0 to 6, and mixtures thereof. </p><p id="p0047" num="0047"> In another aspect, the invention relates to retinyl esters represented by the general formula 1 : 
<!-- EPO <DP n="11"/>-->
 
<img id="imgf000011_0001" he="20" wi="97" file="imgf000011_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/>
 </p><p id="p0048" num="0048">wherein R is selected from substituted and unsubstituted, branched- and straight-chain, saturated, unsaturated, and polyunsaturated divalent C ds alkyl, or C-<sub>1</sub>-C-<sub>12</sub> alkyl, or C-i-C-<sub>10</sub> alkyl, or a saturated or monounsaturated straight-chain C-i-C-<sub>10</sub> alkyl, or C C<sub>4</sub> alkyl ; and R<sup>1</sup> is selected from hydrogen, substituted and unsubstituted, branched- and straight-chain, saturated, unsaturated, and polyunsaturated C ds alkyl, or C<sub>1</sub>-C<sub>12</sub> alkyl, or Ci-C<sub>4</sub> alkyl ; and n is 0-10, or 1 -6, or 1 -4, or mixtures thereof. </p><p id="p0049" num="0049"> In various additional aspects, examples of the compounds of the invention thus include those represented by formula 1 wherein R is methyl, ethyl, or propyl, R<sup>1</sup> is methyl, ethyl, or propyl, and n is from 0 to 6, and mixtures thereof. We note that if different hydroxyl-substituted acids are used in the processes according to the invention, each of the R and R1 groups may exist independently of one another, but that if a single hydroxyl-substituted acid is used, each of the defined R and R1 groups will be the same, and the retinyl esters produced may include oligomers having varying lengths, such that the retinyl esters are mixtures of compounds in which n=0, n=1 , n=2, n=3, etc. However, when n is defined as 0-6, for example, we do not mean to thereby excludes mixtures which contain compounds in which n=7, n=8, etc., although they will typically be present in minor amounts, if at all. </p><p id="p0050" num="0050"> Other examples of the retinyl esters of the invention thus include compounds and mixtures represented by formula 1 wherein R is methylene, R<sup>1</sup> is methyl, and n is from 0 to 6, and mixtures thereof containing compounds in which n=0, n=1 , n=2, n=3, and n=4. </p><p id="p0051" num="0051"> In another aspect of the invention, the retinyl esters correspond to the general formula 1 : 
<!-- EPO <DP n="12"/>-->
</p><p id="p0052" num="0052"><img id="imgf000012_0001" he="20" wi="97" file="imgf000012_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/></p><p id="p0053" num="0053">wherein R is selected from substituted and unsubstituted, branched- and straight-chain, saturated, unsaturated, and polyunsaturated divalent CI -C<sub>22</sub> alkyl, or C-|-C-|<sub>8</sub> alkyl, or C<sub>1</sub>-C-<sub>12</sub> alkyl, or an unsaturated, monounsaturated, or polyunsaturated straight-chain C<sub>2</sub>-C<sub>22</sub> alkyl, or C<sub>4</sub>-Ci<sub>8</sub> alkyl; and R<sup>1</sup> is selected from hydrogen, substituted and unsubstituted, branched- and straight-chain, saturated, unsaturated, and polyunsaturated C ds alkyl, or C<sub>1</sub>-C<sub>12</sub> alkyl, or Ci-C<sub>4</sub> alkyl; and n is 0-10, or 1 -6, or 1 -4, or mixtures thereof. In this aspect, the retinyl esters may be derived from retinol and one or more hydroxy- substituted carboxylic acids, for example 3-hydroxybutyric acid, 3-hydroxy-3- methylbutyric acid, 3-hydroxyoctanoic acid, malic acid, 3-hydroxy-3- methylglutaric acid, 3-phenyl-3-hydroxypropanoic acid, 10-hydroxydecanoic acid, 12-hydroxydodecanoic acid, 16-hydroxyhexadecanoic acid, or ricinoleic acid. </p><p id="p0054" num="0054"> The retinyl esters produced from these hydroxyl-substituted acids may include oligomers comprised of more than one repeating unit from the fatty acid, depending upon the reactivity of the hydroxyl-substituted portion of the acid. </p><p id="p0055" num="0055"> Another embodiment of our invention is a novel enzymatic process for the preparation of retinyl ester compounds represented by the general formula 1 : </p><p id="p0056" num="0056"><img id="imgf000012_0002" he="20" wi="96" file="imgf000012_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></p><p id="p0057" num="0057">wherein, 
<!-- EPO <DP n="13"/>-->
 R is selected from substituted and unsubstituted, branched- and straight- chain, saturated, unsaturated, and polyunsaturated divalent C1 -C22 alkyl, substituted and unsubstituted divalent C<sub>3</sub>-C<sub>8</sub> cycloalkyl, substituted and unsubstituted divalent C<sub>6</sub>-C<sub>2</sub>o carbocyclic aryl, and substituted and </p><p id="p0058" num="0058">unsubstituted divalent C<sub>4</sub>-C<sub>2</sub>o heterocyclic wherein the heteroatoms are selected from sulfur, nitrogen, and oxygen, and R<sup>1</sup> is selected from hydrogen, substituted and unsubstituted, branched- and straight-chain, saturated, unsaturated, and polyunsaturated C1 -C22 alkyl, substituted and unsubstituted C<sub>3</sub>-C<sub>8</sub> cycloalkyl, substituted and unsubstituted C<sub>6</sub>-C<sub>2</sub>o carbocyclic aryl, and substituted and unsubstituted C<sub>4</sub>-C<sub>2</sub>o heterocyclic wherein the heteroatoms are selected from sulfur, nitrogen, and oxygen, the compounds represented by formula 1 may be racemic, enantiomerically enriched, diasteroemerically enriched, substantially diastereomerically pure, or substantially </p><p id="p0059" num="0059">enantiomerically pure, and n is 0-10 or mixtures thereof by reaction of retinol with an acid or short chain ester of a hydroxyalkanoate represented by general formula 2 
<img id="imgf000013_0001" he="12" wi="28" file="imgf000013_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/>
 </p><p id="p0060" num="0060"> 2 wherein R and R<sup>1</sup> are as indicated above and R<sup>5</sup> is chosen from hydrogen or C1 -C5 straight or branched chain alkane or alkene in the presence of a lipase, esterase, or protease. </p><p id="p0061" num="0061"> The process is carried out without solvent or in an inert solvent chosen from cyclic or acyclic ether solvents such as diethyl ether, diisopropyl ether, tert-butyl methyl ether, or tetrahydrofuran, aromatic hydrocarbons such as benzene, toluene, or xylene, aliphatic or alicyclic saturated or unsaturated hydrocarbons such as hexane, heptane, cyclohexane, or limonene, 
<!-- EPO <DP n="14"/>-->
 halogenated hydrocarbons such as dichloromethane, dichloroethane, dibromoethane, tetrachloroethylene, or chlorobenzene, polar aprotic solvents such as acetonitrile, dimethyl formamide, or dimethyl sulfoxide, or mixtures thereof. </p><p id="p0062" num="0062"> The preferred solvents are no solvent, toluene, limonene, heptanes, and acetonitrile. The process may be carried out at a temperature between about - 100 °C and the boiling point of the solvent, preferably about 0-60 °C, most preferably 20-50 °C. The amount of acid or short-chain ester 2 may be between 0.85 and 20 equivalents based on retinol, and is preferably between 1 and 10 equivalents, most preferably between 1 and 4 equivalents. </p><p id="p0063" num="0063"> The enzyme used in the process may be chosen from a variety of hydrolytic enzymes, for example a protease, a lipase, or an esterase. </p><p id="p0064" num="0064">Preferred enzymes include lipases. These lipases may be in the form of whole cells, isolated native enzymes, or immobilized on supports. </p><p id="p0065" num="0065"> Examples of suitable lipases include, but are not limited to, Lipase PS</p><p id="p0066" num="0066">(from Pseudomonas sp), Lipase PS-C (from Psuedomonas sp immobilized on ceramic), Lipase PS-D (from Pseudomonas sp immobilized on diatomaceous earth), Lipoprime 50T, Lipozyme TL IM, or Novozym 435 (Candida antarctica lipase B immobilized on acrylic resin). Removal of the water or alcohol byproducts, if desired, can be done chemically via a water or alcohol absorbent (e.g., molecular sieves) or by physical removal of the water or alcohol. This by-product removal is preferably done by evaporation, either by purging the reaction mixture with an inert gas such as nitrogen, argon, or helium, or by performing the reaction at reduced pressures, or both, as these conditions can afford &gt;95% conversion of retinol to 1. The preferred pressure for the reaction is between 1 torr and ambient pressure, more preferable between 50 torr and ambient pressure. Any organic solvent that is included in this process may or may not be removed along with the water or alcohol. Examples of 2 include ethyl 3-hydroxybutyrate and methyl 3-hydroxybutyrate. 
<!-- EPO <DP n="15"/>-->
 The product 1 of the process may be isolated using methods known to those of skill in the art, e.g., by extraction, filtration, or crystallization. </p><p id="p0067" num="0067"> The retinyl esters according to the present invention can be used in compositions, such as cosmetic compositions, skin care compositions and the like. The compositions can be useful, for example, for reducing skin roughness, fine lines, and wrinkles, improving photo-damaged skin, regenerating skin, reducing skin hyper-pigmentation, and reducing irritation and/or inflammatory reaction in skin. </p><p id="p0068" num="0068"> Typical cosmetic and/or skin care compositions of the invention contain at least 0.001 % by weight of the carbonates according to the present invention. For example, the compositions can contain from about 0.001 % to about 20.0 % by weight or from about 0.01 % to about 10.0 % by weight of the retinyl ester according to the present invention. Lower concentrations may be employed for less pronounced conditions, and higher concentrations may be employed with more acute conditions. Suggested ranges also depend upon any adjunct ingredients employed in the compositions. </p><p id="p0069" num="0069"> The cosmetic and skin care compositions of the invention may also contain other skin conditioning ingredients in addition to retinyl esters. Such compositions may include, but are not limited to, skin care ingredients such as retinol, retinyl fatty acid esters, tetronic acid, tetronic acid derivatives, hydroquinone, kojic acid, gallic acid, arbutin, a-hydroxy acids, ascorbic acid and fatty acid esters of ascorbic acid. Such other ingredients are known to those of skill in the art. </p><p id="p0070" num="0070"> Typically, topical application to skin sites is accomplished in association with a carrier. Where employed, the carrier is desirably inert in the sense of not bringing about a deactivation or oxidation of active or adjunct </p><p id="p0071" num="0071">ingredient(s), and in the sense of not bringing about any significant adverse effect on the skin areas to which it is applied. For example, the compounds according to the present invention may be applied in admixture with a dermatologically acceptable carrier or vehicle (e.g., as a lotion, cream, 
<!-- EPO <DP n="16"/>-->
 ointment, soap, stick, or the like) so as to facilitate topical application and, in some cases, provide additional beneficial effects as might be brought about, e.g., by moisturizing of the affected skin areas. </p><p id="p0072" num="0072"> Suitable preparations include lotions containing oils and/or alcohols and emollients such as olive oil, hydrocarbon oils and waxes, silicone oils, other vegetable, animal or marine fats or oils, glyceride derivatives, fatty acids or fatty acid esters or alcohols or alcohol ethers, lecithin, lanolin and derivatives, polyhydric alcohols or esters, wax esters, sterols, phospholipids and the like, and generally also emulsifiers (nonionic, cationic or anionic), although some of the emollients inherently possess emulsifying properties. These same general ingredients can be formulated into a cream rather than a lotion, or into gels, or into solid sticks by utilization of different proportions of the ingredients and/or by inclusion of thickening agents such as gums or other forms of hydrophilic colloids. </p><p id="p0073" num="0073"> The novel processes provided by the present invention are further illustrated by the following examples. </p><p id="p0074" num="0074">EXAMPLES </p><p id="p0075" num="0075"> Example 1 : </p><p id="p0076" num="0076"> Preparation of Retinyl 3-Hydroxybutyrate (1a) oligomers (n=0-4)</p><p id="p0077" num="0077">To a vial was added retinol in heptane (58% retinol ; 25.9 g ; 1 5.0 g retinol ; 52.4 mmol), ethyl 3-hydroxybutyrate (20.76 g ; 1 57 mmol ; 3 equiv), and Novozym 435 (1 .5 g). The mixture was stirred at room temperature and purged with a stream of nitrogen through the mixture for 48 h to afford 96.7% conversion of retinol to a mixture of retinyl 3-hydroxybutyrate oligomers. The mixture was diluted with toluene (30 mL), filtered and the solid was washed with toluene (30 mL). The toluene solution was washed with 1 :1 </p><p id="p0078" num="0078">watenmethanol (60 mL) and the aqueous decant was back-extracted with heptanes (25 mL). The combined organic layer was washed with 1 :1 watenmethanol (60 mL), dried with sodium sulfate, and concentrated to afford 
<!-- EPO <DP n="17"/>-->
 indicated 3.7% retinol and 95.5% 1a oligomers. The proportion by HPLC is 1 a, n=0 (53.7%), 1a, n=1 (32.9%), 1 a, n=2 (7.1 %), 1a, n=3 (1 .4%), and 1 a, n=4 (0.3%). </p><p id="p0079" num="0079"> HPLC and HPLC-MS (4.6 x 1 50 mm Zorbax SB-C8 column [Agilent], 3.5 μ thickness, 80:20 methanol :water (containing 0.1 % trifluoroacetic acid) for 20 min, detection at 325 nm): t<sub>R</sub> 6.6 min (retinol); t<sub>R</sub> 8.0 min (1a, n=0, M<sup>+</sup> = 372 ) ; t<sub>R</sub> 8.8 min (1a, n=1 , M<sup>+</sup> = 458) ; t<sub>R</sub> 9.7 min (1 a, n=2, M<sup>+</sup> = 544) ; t<sub>R</sub> 1 0.6 min (1 a, n=3, M<sup>+</sup> = 630) ; t<sub>R</sub> 1 1 .8 min (1a, n=4, M<sup>+</sup> = 716). </p><p id="p0080" num="0080">Example 2: </p><p id="p0081" num="0081"> Preparation of Retinyl Ricinoleate (1b) </p><p id="p0082" num="0082"> To a vial was added retinol in toluene (54% retinol ; 1 .852 g ; 1 .0 g retinol ; 3.49 mmol), ricinoleic acid (80%; 1 .250 g; 4.1 9 mmol ; 1 .2 equiv), and </p><p id="p0083" num="0083">Novozym 435 (1 g). The mixture was sealed and stirred at room temperature for 21 h to afford 83% conversion of retinol to 1 b. </p><p id="p0084" num="0084"> HPLC (4.6 x 1 50 mm Zorbax SB-C8 column [Agilent], 3.5 μ thickness, 90:10 methanol :water (containing 0.1 % trifluoroacetic acid) for 7 min, gradient to 95:5 methanol :water (containing 0.1 % trifluoroacetic acid) over 1 min, hold for 1 2 min, gradient to 1 00% methanol over 1 min, hold at 1 00% methanol, detection at 325 nm) : t<sub>R</sub> 3.9 min (retinol) ; t<sub>R</sub> 14.2 min (1 b ). </p><p id="p0085" num="0085">Example 3: </p><p id="p0086" num="0086"> Enzymatic Hydrolysis of Retinyl 3-Hydroxybutyrate (1a) oligomers (n=0-4)</p><p id="p0087" num="0087">Retinyl 3-hydroxybutyrate oligomers (1 a; 100 mg) was dissolved in 2 mL of toluene. pH 7 Buffer (2 mL) was added. Novozym 435 (1 00 mg) was added, and the mixture was stirred vigorously at ambient temperature. The top layer was sampled at 1 , 24, and 48 h and analyzed by HPLC. The results are shown in Table 1 , and indicate significant hydrolysis to retinol over 48h. A control reaction without enzyme showed no hydrolysis after 48 h. 
<!-- EPO <DP n="18"/>-->
 Table 1 - Enzymatic Hydrolysis of Retinyl 3-Hydroxybutyrate Oligomers </p><p id="p0088" num="0088"><img id="imgf000018_0001" he="66" wi="153" file="imgf000018_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="yes"/></p></description><claims mxw-id="PCLM46160906" ref-ucid="WO-2012154243-A1" lang="EN" load-source="patent-office"><claim-statement><!-- EPO <DP n="19"/>-->THAT WHICH IS CLAIMED IS: </claim-statement><claim id="clm-0001" num="1"><claim-text>1 . Retinyl esters represented by the general formula 1 :</claim-text><claim-text> <img id="imgf000019_0001" he="20" wi="96" file="imgf000019_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/> </claim-text><claim-text>wherein, </claim-text><claim-text> R is selected from substituted and unsubstituted, branched- and straight-chain, saturated, unsaturated, and polyunsaturated divalent C1 -C22 alkyl, substituted and unsubstituted divalent C<sub>3</sub>-C<sub>8</sub> cycloalkyi, substituted and unsubstituted divalent C<sub>6</sub>-C<sub>2</sub>o carbocyclic aryl, and substituted and </claim-text><claim-text>unsubstituted divalent C<sub>4</sub>-C<sub>2</sub>o heterocyclic wherein the heteroatoms are selected from sulfur, nitrogen, and oxygen; </claim-text><claim-text> R<sup>1</sup> is selected from hydrogen, substituted and unsubstituted, branched- and straight-chain, saturated, unsaturated, and polyunsaturated C1 -C22 alkyl, substituted and unsubstituted C<sub>3</sub>-C<sub>8</sub> cycloalkyi, substituted and unsubstituted C<sub>6</sub>-C<sub>2</sub>o carbocyclic aryl, and substituted and unsubstituted C<sub>4</sub>-C<sub>2</sub>o heterocyclic wherein the heteroatoms are selected from sulfur, nitrogen, and oxygen; and n is 0-10. </claim-text><claim-text> or mixtures thereof. </claim-text></claim><claim id="clm-0002" num="2"><claim-text>2. The retinyl esters of claim 1 , wherein R is a substituted or </claim-text><claim-text>unsubstituted, branched- or straight-chain, saturated, unsaturated, or polyunsaturated divalent C-i-do alkyl, or a saturated or monounsaturated straight-chain C1-C4 alkyl; and R<sup>1</sup> is hydrogen, a substituted or unsubstituted, branched- or straight-chain, saturated, unsaturated, or polyunsaturated C-|-C-|<sub>8</sub> alkyl, or C1-C-12 alkyl, or C C<sub>4</sub> alkyl; and n is 0-6, or mixtures thereof. <!-- EPO <DP n="20"/>--> </claim-text></claim><claim id="clm-0003" num="3"><claim-text>3. The retinyl esters of claim 1 , wherein R is methylene, ethylene, or propylene; R<sup>1</sup> is methyl, ethyl, or propyl; and n is from 0 to 6, or mixtures thereof. </claim-text></claim><claim id="clm-0004" num="4"><claim-text>4. The retinyl esters of claim 1 , wherein R is methylene; R<sup>1</sup> is methyl, and n= 0, 1 , 2, 3, and 4. </claim-text></claim><claim id="clm-0005" num="5"><claim-text>5. The retinyl esters of claim 1 , wherein the retinyl esters are derived from retinol and one or more hydroxy-substituted carboxylic acids. </claim-text></claim><claim id="clm-0006" num="6"><claim-text>6. The retinyl esters of claim 5, wherein the one or more hydroxy- substituted carboxylic acids comprise one or more of 3-hydroxybutyric acid, 3-hydroxy-3-methylbutyric acid, 3-hydroxyoctanoic acid, malic acid, 3- hydroxy-3-methylglutaric acid, 3-phenyl-3-hydroxypropanoic acid, 10- hydroxydecanoic acid, 12-hydroxydodecanoic acid, 16-hydroxyhexadecanoic acid, or ricinoleic acid. </claim-text></claim><claim id="clm-0007" num="7"><claim-text>7. The retinyl esters of claim 5, wherein the esters include oligomers comprised of more than one repeating unit from the one or more hydroxy- substituted carboxylic acids. </claim-text></claim><claim id="clm-0008" num="8"><claim-text>8. A process for producing the retinyl esters of claim 1 , the process comprising reacting retinol, in the presence of an enzyme, with an acid or short chain ester of a hydroxyalkanoate represented by formula 2 <img id="imgf000020_0001" he="12" wi="28" file="imgf000020_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/> </claim-text><claim-text> 2 <!-- EPO <DP n="21"/>--> wherein R and R<sup>1</sup> are as indicated in claim 1 , and R<sup>5</sup> is chosen from hydrogen or C1 -C5 straight or branched chain alkane or alkene. </claim-text></claim><claim id="clm-0009" num="9"><claim-text>9. The process of claim 8, wherein the process is carried out in a solvent chosen from diethyl ether, diisopropyl ether, tert-butyl methyl ether, tetrahydrofuran, benzene, toluene, xylene, hexane, heptane, cyclohexane, limonene, dichloromethane, dichloroethane, dibromoethane, </claim-text><claim-text>tetrachloroethylene, chlorobenzene, acetonitrile, dimethyl formamide, or dimethyl sulfoxide, or mixtures thereof. </claim-text></claim><claim id="clm-0010" num="10"><claim-text>10. The process of claim 9, wherein the solvent chosen from one or more of toluene, limonene, heptane, or acetonitrile. </claim-text></claim><claim id="clm-0011" num="11"><claim-text>1 1 . The process of claim 8, wherein the process is carried out in the absence of a solvent. </claim-text></claim><claim id="clm-0012" num="12"><claim-text>12. The process of claim 8, wherein the enzyme comprises one or more of a lipase, an esterase, or a protease. </claim-text></claim><claim id="clm-0013" num="13"><claim-text>13. The process of claim 8, wherein the enzyme is a lipase. </claim-text></claim><claim id="clm-0014" num="14"><claim-text>14. The process of claim 8, wherein the acid or short chain ester of a hydroxyalkanoate represented by formula 2 comprises one or more of ethyl 3- hydroxybutyrate , methyl 3-hydroxybutyrate, or ricinoleic acid. </claim-text></claim><claim id="clm-0015" num="15"><claim-text>15. A cosmetic composition comprising the retinyl esters of claim 1 . </claim-text></claim></claims><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
